MK-8931
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Amnestic Mild Cognitive Impairment
Conditions
Amnestic Mild Cognitive Impairment, Alzheimer's Disease, Prodromal Alzheimer's Disease
Trial Timeline
Oct 11, 2016 → Apr 12, 2017
NCT ID
NCT02910739About MK-8931
MK-8931 is a phase 1 stage product being developed by Merck for Amnestic Mild Cognitive Impairment. The current trial status is completed. This product is registered under clinical trial identifier NCT02910739. Target conditions include Amnestic Mild Cognitive Impairment, Alzheimer's Disease, Prodromal Alzheimer's Disease.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02910739 | Phase 1 | Completed |
| NCT01537757 | Phase 1 | Completed |
Competing Products
1 competing product in Amnestic Mild Cognitive Impairment
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Verubecestat 12 mg (Parts 1 and 2) + Verubecestat 40 mg (Parts 1 and 2) | Merck | Phase 3 | 77 |